| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 49 | 2026 | 259 | 11.700 |
Why?
|
| Prostatic Neoplasms | 39 | 2024 | 972 | 6.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 34 | 2026 | 1998 | 4.110 |
Why?
|
| Carcinoma, Transitional Cell | 15 | 2026 | 70 | 3.610 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 19 | 2024 | 54 | 3.590 |
Why?
|
| Antineoplastic Agents | 30 | 2025 | 2219 | 3.420 |
Why?
|
| Kidney Neoplasms | 23 | 2023 | 419 | 3.410 |
Why?
|
| Carcinoma, Renal Cell | 18 | 2023 | 231 | 3.010 |
Why?
|
| Neoadjuvant Therapy | 13 | 2026 | 475 | 2.450 |
Why?
|
| Androgen Antagonists | 15 | 2024 | 91 | 2.370 |
Why?
|
| Medical Oncology | 6 | 2026 | 345 | 1.960 |
Why?
|
| Cisplatin | 16 | 2026 | 347 | 1.860 |
Why?
|
| Prednisone | 15 | 2024 | 229 | 1.820 |
Why?
|
| Neoplasm Invasiveness | 12 | 2026 | 504 | 1.590 |
Why?
|
| Urologic Neoplasms | 7 | 2026 | 31 | 1.510 |
Why?
|
| Pyrroles | 7 | 2017 | 222 | 1.490 |
Why?
|
| Cystectomy | 10 | 2026 | 46 | 1.280 |
Why?
|
| Indoles | 8 | 2019 | 511 | 1.260 |
Why?
|
| Taxoids | 8 | 2025 | 115 | 1.250 |
Why?
|
| Neoplasm Metastasis | 25 | 2025 | 693 | 1.230 |
Why?
|
| Androstenes | 6 | 2024 | 16 | 1.220 |
Why?
|
| Abiraterone Acetate | 9 | 2021 | 15 | 1.220 |
Why?
|
| Urothelium | 3 | 2016 | 33 | 1.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2026 | 992 | 1.170 |
Why?
|
| Neoplasm Staging | 14 | 2024 | 1488 | 1.110 |
Why?
|
| Phenylurea Compounds | 6 | 2016 | 122 | 1.000 |
Why?
|
| Adenocarcinoma | 7 | 2020 | 927 | 0.990 |
Why?
|
| Mitoxantrone | 5 | 2018 | 14 | 0.990 |
Why?
|
| Prostate-Specific Antigen | 12 | 2024 | 162 | 0.980 |
Why?
|
| Male | 99 | 2026 | 73396 | 0.980 |
Why?
|
| Humans | 144 | 2026 | 146342 | 0.960 |
Why?
|
| Antineoplastic Agents, Hormonal | 8 | 2017 | 196 | 0.960 |
Why?
|
| Aged | 64 | 2026 | 26432 | 0.920 |
Why?
|
| Niacinamide | 5 | 2016 | 103 | 0.910 |
Why?
|
| Orchiectomy | 4 | 2014 | 72 | 0.910 |
Why?
|
| Mineralocorticoids | 1 | 2024 | 7 | 0.860 |
Why?
|
| Aged, 80 and over | 31 | 2026 | 8391 | 0.820 |
Why?
|
| Carcinoma, Small Cell | 1 | 2024 | 172 | 0.820 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2025 | 135 | 0.800 |
Why?
|
| Penile Neoplasms | 1 | 2023 | 7 | 0.780 |
Why?
|
| Phenylthiohydantoin | 7 | 2024 | 44 | 0.780 |
Why?
|
| Antibodies, Monoclonal | 9 | 2026 | 1512 | 0.760 |
Why?
|
| Carcinoma | 2 | 2016 | 225 | 0.710 |
Why?
|
| Testicular Neoplasms | 3 | 2023 | 108 | 0.710 |
Why?
|
| Middle Aged | 54 | 2026 | 36619 | 0.690 |
Why?
|
| ErbB Receptors | 6 | 2018 | 636 | 0.680 |
Why?
|
| Nitriles | 11 | 2024 | 212 | 0.660 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2026 | 429 | 0.650 |
Why?
|
| Treatment Outcome | 29 | 2024 | 11821 | 0.630 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2014 | 983 | 0.620 |
Why?
|
| Immunotherapy | 5 | 2022 | 671 | 0.620 |
Why?
|
| Prognosis | 14 | 2026 | 4351 | 0.590 |
Why?
|
| Radiosurgery | 4 | 2015 | 398 | 0.550 |
Why?
|
| Deoxycytidine | 6 | 2025 | 219 | 0.550 |
Why?
|
| Disease-Free Survival | 12 | 2017 | 778 | 0.540 |
Why?
|
| Urinary Bladder | 4 | 2026 | 194 | 0.540 |
Why?
|
| Benzamides | 8 | 2024 | 226 | 0.530 |
Why?
|
| Bone Neoplasms | 3 | 2015 | 272 | 0.530 |
Why?
|
| Viscera | 2 | 2014 | 17 | 0.530 |
Why?
|
| Hematologic Diseases | 2 | 2016 | 66 | 0.520 |
Why?
|
| Sulfonamides | 2 | 2012 | 594 | 0.520 |
Why?
|
| Prostatectomy | 5 | 2018 | 93 | 0.510 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2016 | 14 | 0.490 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 200 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1591 | 0.470 |
Why?
|
| Databases, Factual | 5 | 2024 | 1493 | 0.460 |
Why?
|
| Receptors, Androgen | 2 | 2021 | 149 | 0.460 |
Why?
|
| BCG Vaccine | 3 | 2024 | 26 | 0.450 |
Why?
|
| Pancreatitis | 1 | 2016 | 146 | 0.440 |
Why?
|
| Silymarin | 4 | 2013 | 147 | 0.440 |
Why?
|
| Genomics | 2 | 2018 | 853 | 0.420 |
Why?
|
| Doxorubicin | 3 | 2026 | 416 | 0.420 |
Why?
|
| Retrospective Studies | 16 | 2024 | 17438 | 0.420 |
Why?
|
| Leydig Cell Tumor | 1 | 2014 | 8 | 0.410 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 776 | 0.410 |
Why?
|
| DNA Damage | 3 | 2025 | 439 | 0.400 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2016 | 219 | 0.380 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 250 | 0.360 |
Why?
|
| Neoplasms | 3 | 2025 | 2954 | 0.360 |
Why?
|
| Hypothyroidism | 1 | 2012 | 68 | 0.360 |
Why?
|
| Organ Sparing Treatments | 2 | 2025 | 37 | 0.350 |
Why?
|
| United States | 12 | 2026 | 16136 | 0.350 |
Why?
|
| Multicenter Studies as Topic | 2 | 2021 | 417 | 0.350 |
Why?
|
| Administration, Intravesical | 3 | 2022 | 15 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2026 | 970 | 0.350 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 18 | 0.350 |
Why?
|
| Adult | 30 | 2026 | 41087 | 0.350 |
Why?
|
| Diethylstilbestrol | 1 | 2011 | 4 | 0.350 |
Why?
|
| Pyrazoles | 3 | 2024 | 517 | 0.340 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1792 | 0.340 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 76 | 0.340 |
Why?
|
| Angiomyolipoma | 1 | 2011 | 21 | 0.340 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 109 | 0.340 |
Why?
|
| Female | 36 | 2026 | 79499 | 0.330 |
Why?
|
| Sarcoma | 1 | 2013 | 209 | 0.330 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 81 | 0.320 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2008 | 702 | 0.310 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2010 | 70 | 0.300 |
Why?
|
| Disease Progression | 10 | 2021 | 2867 | 0.300 |
Why?
|
| Lung Neoplasms | 5 | 2017 | 2675 | 0.300 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 444 | 0.300 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 663 | 0.300 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 447 | 0.300 |
Why?
|
| Androgen Receptor Antagonists | 4 | 2024 | 35 | 0.300 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 57 | 0.300 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2010 | 178 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 530 | 0.290 |
Why?
|
| Lymphatic Diseases | 1 | 2009 | 21 | 0.290 |
Why?
|
| SEER Program | 4 | 2023 | 233 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2009 | 77 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2019 | 545 | 0.290 |
Why?
|
| Cystitis | 1 | 2009 | 24 | 0.290 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2026 | 141 | 0.280 |
Why?
|
| Androstadienes | 3 | 2013 | 77 | 0.280 |
Why?
|
| Neuroblastoma | 1 | 2010 | 177 | 0.270 |
Why?
|
| Muscles | 3 | 2024 | 330 | 0.270 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2008 | 21 | 0.270 |
Why?
|
| Survival Rate | 9 | 2021 | 2092 | 0.270 |
Why?
|
| Intestinal Perforation | 1 | 2008 | 46 | 0.270 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 2 | 2024 | 6 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 628 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 1160 | 0.260 |
Why?
|
| Double-Blind Method | 12 | 2021 | 2070 | 0.260 |
Why?
|
| Clinical Trials as Topic | 5 | 2018 | 1064 | 0.250 |
Why?
|
| Pyrimidines | 1 | 2011 | 532 | 0.250 |
Why?
|
| Precision Medicine | 1 | 2011 | 462 | 0.250 |
Why?
|
| Pharmacogenetics | 2 | 2026 | 176 | 0.250 |
Why?
|
| Cell Line, Tumor | 8 | 2025 | 3545 | 0.250 |
Why?
|
| Survival Analysis | 6 | 2021 | 1378 | 0.250 |
Why?
|
| Testosterone | 3 | 2021 | 419 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2024 | 2786 | 0.240 |
Why?
|
| Combined Modality Therapy | 9 | 2020 | 1271 | 0.240 |
Why?
|
| Nanotubes | 2 | 2018 | 46 | 0.240 |
Why?
|
| Quinazolines | 4 | 2019 | 267 | 0.240 |
Why?
|
| Methotrexate | 2 | 2025 | 234 | 0.240 |
Why?
|
| Cardiotoxicity | 1 | 2026 | 35 | 0.240 |
Why?
|
| Biomarkers, Tumor | 5 | 2024 | 1339 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 944 | 0.230 |
Why?
|
| Anilides | 5 | 2023 | 83 | 0.230 |
Why?
|
| Carboplatin | 1 | 2006 | 168 | 0.230 |
Why?
|
| Neoplasm Grading | 6 | 2018 | 313 | 0.230 |
Why?
|
| Gold | 2 | 2018 | 118 | 0.230 |
Why?
|
| Thiohydantoins | 2 | 2024 | 5 | 0.230 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 806 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2024 | 1408 | 0.220 |
Why?
|
| Vinca Alkaloids | 1 | 2025 | 6 | 0.220 |
Why?
|
| Dendrimers | 1 | 2025 | 21 | 0.220 |
Why?
|
| Bridged-Ring Compounds | 1 | 2025 | 31 | 0.220 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2020 | 215 | 0.220 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 335 | 0.220 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2024 | 1 | 0.210 |
Why?
|
| Hypokalemia | 1 | 2024 | 23 | 0.210 |
Why?
|
| Recombinational DNA Repair | 1 | 2024 | 19 | 0.210 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2024 | 10 | 0.210 |
Why?
|
| Hematuria | 1 | 2024 | 11 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2018 | 222 | 0.210 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 69 | 0.210 |
Why?
|
| Drug Carriers | 1 | 2025 | 138 | 0.210 |
Why?
|
| Nanostructures | 1 | 2025 | 105 | 0.200 |
Why?
|
| Vinblastine | 1 | 2024 | 75 | 0.200 |
Why?
|
| Drug Synergism | 3 | 2011 | 354 | 0.200 |
Why?
|
| Dexamethasone | 1 | 2006 | 368 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 893 | 0.200 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 747 | 0.200 |
Why?
|
| Societies, Medical | 2 | 2018 | 907 | 0.200 |
Why?
|
| Androstenols | 3 | 2015 | 4 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 1763 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2013 | 2022 | 0.190 |
Why?
|
| Tosyl Compounds | 4 | 2018 | 17 | 0.190 |
Why?
|
| Drug Administration Schedule | 4 | 2021 | 790 | 0.190 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 2 | 2014 | 5 | 0.190 |
Why?
|
| Lymph Node Excision | 3 | 2026 | 174 | 0.190 |
Why?
|
| Vitamin D | 1 | 2006 | 402 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 40 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 1432 | 0.180 |
Why?
|
| Retroperitoneal Space | 1 | 2021 | 19 | 0.180 |
Why?
|
| Tissue Extracts | 2 | 2012 | 19 | 0.170 |
Why?
|
| Indazoles | 2 | 2012 | 86 | 0.170 |
Why?
|
| Kallikreins | 2 | 2019 | 25 | 0.170 |
Why?
|
| Retreatment | 1 | 2021 | 79 | 0.160 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2024 | 198 | 0.160 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 301 | 0.160 |
Why?
|
| Quality of Life | 4 | 2024 | 3200 | 0.160 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 67 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2024 | 516 | 0.150 |
Why?
|
| Phosphatidylcholines | 2 | 2013 | 131 | 0.150 |
Why?
|
| Time Factors | 5 | 2020 | 7109 | 0.150 |
Why?
|
| Yttrium | 1 | 2018 | 5 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 239 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 334 | 0.140 |
Why?
|
| Euterpe | 1 | 2018 | 4 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 180 | 0.140 |
Why?
|
| Fluorides | 1 | 2018 | 50 | 0.140 |
Why?
|
| Apoptosis | 1 | 2007 | 2439 | 0.140 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 7 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2021 | 1077 | 0.130 |
Why?
|
| Antioxidants | 2 | 2013 | 544 | 0.130 |
Why?
|
| Central Nervous System | 1 | 2020 | 278 | 0.130 |
Why?
|
| Piperidines | 2 | 2010 | 225 | 0.130 |
Why?
|
| Congresses as Topic | 2 | 2012 | 226 | 0.130 |
Why?
|
| Tumor Escape | 1 | 2018 | 50 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1537 | 0.130 |
Why?
|
| History, 21st Century | 2 | 2015 | 224 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 3 | 2018 | 404 | 0.130 |
Why?
|
| Genome | 1 | 2020 | 307 | 0.130 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 161 | 0.130 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 143 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2240 | 0.130 |
Why?
|
| Blotting, Western | 2 | 2010 | 1177 | 0.130 |
Why?
|
| Proton Therapy | 1 | 2017 | 16 | 0.130 |
Why?
|
| Biopsy | 3 | 2018 | 1075 | 0.120 |
Why?
|
| Goserelin | 3 | 2018 | 8 | 0.120 |
Why?
|
| Erythrocyte Indices | 1 | 2016 | 33 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2018 | 192 | 0.120 |
Why?
|
| Aftercare | 1 | 2018 | 225 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2025 | 1210 | 0.120 |
Why?
|
| Fatal Outcome | 2 | 2008 | 302 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2018 | 264 | 0.120 |
Why?
|
| Mutation | 2 | 2024 | 4093 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2018 | 184 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 2488 | 0.120 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2016 | 81 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2016 | 90 | 0.120 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 208 | 0.110 |
Why?
|
| Prostate | 2 | 2021 | 159 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 539 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 3926 | 0.110 |
Why?
|
| Disease Management | 1 | 2019 | 651 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 101 | 0.110 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2014 | 13 | 0.100 |
Why?
|
| Ablation Techniques | 1 | 2014 | 36 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 133 | 0.100 |
Why?
|
| Mitotic Index | 1 | 2014 | 24 | 0.100 |
Why?
|
| Patient Selection | 1 | 2018 | 728 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 33 | 0.100 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2018 | 536 | 0.100 |
Why?
|
| Insurance, Health | 1 | 2016 | 318 | 0.100 |
Why?
|
| beta-Galactosidase | 1 | 2013 | 73 | 0.100 |
Why?
|
| Carcinoma, Medullary | 1 | 2013 | 16 | 0.100 |
Why?
|
| Breeding | 1 | 2013 | 64 | 0.100 |
Why?
|
| Keratins | 1 | 2013 | 57 | 0.100 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 119 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 2014 | 434 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2026 | 2418 | 0.100 |
Why?
|
| Staining and Labeling | 1 | 2013 | 148 | 0.090 |
Why?
|
| Hyperplasia | 1 | 2013 | 164 | 0.090 |
Why?
|
| Urogenital Neoplasms | 1 | 2012 | 5 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 33 | 0.090 |
Why?
|
| Sirolimus | 2 | 2014 | 282 | 0.090 |
Why?
|
| Geriatrics | 1 | 2014 | 96 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2013 | 307 | 0.090 |
Why?
|
| Pyridines | 2 | 2023 | 610 | 0.090 |
Why?
|
| Integrases | 1 | 2013 | 117 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 345 | 0.090 |
Why?
|
| Adenoviridae | 1 | 2013 | 197 | 0.090 |
Why?
|
| Bevacizumab | 2 | 2025 | 169 | 0.090 |
Why?
|
| Nephrectomy | 2 | 2013 | 172 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2012 | 2502 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 3416 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2015 | 481 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2018 | 523 | 0.090 |
Why?
|
| Celecoxib | 1 | 2012 | 41 | 0.090 |
Why?
|
| Thyroid Hormones | 1 | 2012 | 69 | 0.090 |
Why?
|
| Bone Diseases | 1 | 2012 | 60 | 0.090 |
Why?
|
| RNA, Untranslated | 1 | 2013 | 125 | 0.090 |
Why?
|
| Thyroid Gland | 1 | 2012 | 93 | 0.090 |
Why?
|
| Quinolines | 1 | 2013 | 191 | 0.090 |
Why?
|
| Animals | 6 | 2025 | 38107 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1325 | 0.080 |
Why?
|
| Imidazoles | 1 | 2012 | 245 | 0.080 |
Why?
|
| Cross-Over Studies | 3 | 2021 | 615 | 0.080 |
Why?
|
| Denosumab | 1 | 2010 | 10 | 0.080 |
Why?
|
| RANK Ligand | 1 | 2010 | 29 | 0.080 |
Why?
|
| PubMed | 1 | 2010 | 15 | 0.080 |
Why?
|
| Reoperation | 1 | 2014 | 645 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 23 | 0.080 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2010 | 71 | 0.080 |
Why?
|
| Vimentin | 1 | 2010 | 47 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 32 | 0.080 |
Why?
|
| Cell Separation | 1 | 2011 | 300 | 0.080 |
Why?
|
| Mesoderm | 1 | 2010 | 147 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2026 | 5439 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 370 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 930 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 882 | 0.070 |
Why?
|
| Hypertension | 1 | 2018 | 1272 | 0.070 |
Why?
|
| Mice | 3 | 2025 | 18297 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 83 | 0.070 |
Why?
|
| Nephrolithiasis | 1 | 2009 | 10 | 0.070 |
Why?
|
| Gynecomastia | 1 | 2008 | 6 | 0.070 |
Why?
|
| Metaplasia | 1 | 2009 | 54 | 0.070 |
Why?
|
| Cadherins | 1 | 2010 | 202 | 0.070 |
Why?
|
| Risk | 1 | 2011 | 920 | 0.070 |
Why?
|
| Age Factors | 1 | 2016 | 3347 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 453 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 1879 | 0.070 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 2219 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 2134 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 1036 | 0.070 |
Why?
|
| Southwestern United States | 1 | 2008 | 93 | 0.070 |
Why?
|
| Mediastinal Diseases | 1 | 2007 | 10 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 320 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 2007 | 21 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 1331 | 0.060 |
Why?
|
| Liver Failure, Acute | 1 | 2008 | 78 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2008 | 107 | 0.060 |
Why?
|
| Risk Factors | 5 | 2018 | 10921 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 576 | 0.060 |
Why?
|
| Glucuronides | 1 | 2006 | 18 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 103 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2007 | 117 | 0.060 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2006 | 82 | 0.060 |
Why?
|
| Excipients | 1 | 2006 | 55 | 0.060 |
Why?
|
| Liver Function Tests | 1 | 2006 | 103 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 116 | 0.060 |
Why?
|
| Zimbabwe | 1 | 2026 | 76 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 380 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 175 | 0.060 |
Why?
|
| Young Adult | 5 | 2024 | 14330 | 0.060 |
Why?
|
| Pedigree | 1 | 2007 | 512 | 0.060 |
Why?
|
| Radiography | 1 | 2008 | 861 | 0.060 |
Why?
|
| Sarcoidosis | 1 | 2007 | 164 | 0.060 |
Why?
|
| Everolimus | 2 | 2017 | 112 | 0.060 |
Why?
|
| Drug Liberation | 1 | 2025 | 36 | 0.060 |
Why?
|
| Forecasting | 1 | 2007 | 388 | 0.050 |
Why?
|
| Chitosan | 1 | 2025 | 39 | 0.050 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 364 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 5246 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1503 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 69 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 84 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 220 | 0.050 |
Why?
|
| Melanoma | 1 | 2011 | 765 | 0.050 |
Why?
|
| Cystoscopy | 1 | 2024 | 21 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2010 | 1119 | 0.050 |
Why?
|
| Radiotherapy | 2 | 2015 | 209 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2024 | 788 | 0.050 |
Why?
|
| Biomarkers | 2 | 2023 | 4340 | 0.050 |
Why?
|
| Echocardiography | 1 | 2026 | 645 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 1712 | 0.050 |
Why?
|
| Quinoxalines | 1 | 2023 | 65 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1195 | 0.050 |
Why?
|
| Incidence | 2 | 2026 | 2936 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 198 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2009 | 881 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2013 | 217 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2026 | 8123 | 0.040 |
Why?
|
| Steroid Synthesis Inhibitors | 1 | 2021 | 1 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 4580 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2002 | 43 | 0.040 |
Why?
|
| Policy | 1 | 2022 | 147 | 0.040 |
Why?
|
| Prednisolone | 1 | 2021 | 65 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 116 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2002 | 114 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 423 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 384 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 102 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 326 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 441 | 0.040 |
Why?
|
| Nectins | 1 | 2020 | 7 | 0.040 |
Why?
|
| Proteomics | 1 | 2007 | 1203 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 287 | 0.040 |
Why?
|
| Mass Screening | 1 | 2008 | 1307 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 455 | 0.040 |
Why?
|
| Ytterbium | 1 | 2018 | 2 | 0.040 |
Why?
|
| HLA-A2 Antigen | 1 | 2019 | 36 | 0.040 |
Why?
|
| Erbium | 1 | 2018 | 4 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 266 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 738 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 154 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 75 | 0.030 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2018 | 23 | 0.030 |
Why?
|
| Lasers | 1 | 2018 | 127 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2008 | 3712 | 0.030 |
Why?
|
| Pain | 1 | 2024 | 790 | 0.030 |
Why?
|
| Hydrogels | 1 | 2025 | 708 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 158 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2023 | 725 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 56 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2021 | 487 | 0.030 |
Why?
|
| Antibodies | 1 | 2018 | 400 | 0.030 |
Why?
|
| DNA | 1 | 2023 | 1421 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 220 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 104 | 0.030 |
Why?
|
| Thoracic Neoplasms | 1 | 2015 | 40 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 2015 | 48 | 0.030 |
Why?
|
| Placebos | 1 | 2015 | 192 | 0.030 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2014 | 13 | 0.030 |
Why?
|
| Nanoconjugates | 1 | 2014 | 2 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 150 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 872 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 143 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2018 | 442 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 449 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 499 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 519 | 0.030 |
Why?
|
| Benchmarking | 1 | 2015 | 193 | 0.020 |
Why?
|
| Lipids | 1 | 2018 | 714 | 0.020 |
Why?
|
| Cell Death | 1 | 2014 | 379 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2015 | 227 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 96 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2018 | 1765 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2011 | 141 | 0.020 |
Why?
|
| Health Policy | 1 | 2014 | 399 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 219 | 0.020 |
Why?
|
| Androgens | 1 | 2011 | 179 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 650 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1543 | 0.020 |
Why?
|
| Fatigue | 1 | 2011 | 363 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 2107 | 0.020 |
Why?
|
| Seizures | 1 | 2012 | 489 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 343 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 116 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 88 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 22557 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 1105 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2008 | 563 | 0.010 |
Why?
|